Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ARROWHEAD PHARMACEUTICALS, INC. reported revenue of $829M, up 23258.2% year over year. Operating margin was 11.9% and net margin -0.2%, on a free-cash-flow margin of 18.9% with capital expenditure at 2.7% of revenue. Every figure is computed directly from ARWR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $829M | 11.9% | -0.2% |
| FY2024 | $4M | -16927.1% | -16882.4% |
| FY2023 | $241M | -85.2% | -85.3% |
| FY2022 | $243M | -73.4% | -72.4% |
| FY2021 | $138M | -107.8% | -101.9% |
How does ARWR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.